Login / Signup

Frailty as a novel predictor of achieving comprehensive disease control (CDC) in rheumatoid arthritis.

Fausto SalaffiRossella De AngelisSonia FarahMarina CarottiMarco Di Carlo
Published in: Clinical rheumatology (2021)
Frailty, measured by CRAF, reduced the likelihood of CDC achievement in RA patients treated with a biologic agent. Key Points • Frailty is an under-researched condition in rheumatoid arthritis affecting more than 60% of patients. • Frailty is a condition that hinders the achievement of comprehensive disease control after 1 year of treatment with biological drugs in patients with rheumatoid arthritis.
Keyphrases